این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Acta Medica Iranica، جلد ۴۹، شماره ۸، صفحات ۵۰۴-۵۰۸
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Arsenic Trioxide in Patients with Refractory Multiple Myeloma: A Prospective, Phase II, Single-Arm Study
چکیده انگلیسی مقاله Multiple myeloma (MM) characterized by proliferation of plasma cells in bone marrow and production of monoclonal immunoglobulin's. Recently, arsenic trioxide (ATO), has been considered for treatment refractory MM. We assessed the safety and efficacy of ATO for patients with refractory MM. A phase 2, study of arsenic trioxide was conducted in 12 MM patients, whose refractory to two standard therapy. Patients received arsenic trioxide, 0.25 mg/kg/d for 5 d/week during the first 2 consecutive weeks of each 4-week cycle with 2 week rest. Patients who completed one 4-week cycle were evaluated for response to treatment. Twelve patients with refractory multiple myeloma received ATO. Disease assessment was based the amount of serum proteins electrophoresis. Of the10 patients; stable disease was observed in four patients(33%), progression disease in five patients (41.6%), complete response in one patient (3.8%) and the remaining two patients could not be assessed for a response (because of increased liver enzymes after the first week). Some adverse events: increase liver enzymes and serum creatinine, neutropenia, pruritus, nausea, vomiting, lower extremities edema, noninfectious diarrhea was observed. These results indicate that ATO is active and well tolerated as a single-agent salvage therapy, even in patients with late-stage, refractory MM.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله زهره صناعت | zohreh sanaat
hematology and oncology research center, tabriz university of medical sciences, tabriz, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

مهتاب رضازاده | mahtab rezazadeh
hematology and oncology research center, tabriz university of medical sciences, tabriz, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

jalial واعظ قراملکی | jalial vaez gharamaleki
hematology and oncology research center, tabriz university of medical sciences, tabriz, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

جمال عیوضی ضیایی | jamal eivazi ziae
hematology and oncology research center, tabriz university of medical sciences, tabriz, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

علی اصفهانی | ali esfahani
hematology and oncology research center, tabriz university of medical sciences, tabriz, iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تبریز (Tabriz university of medical sciences)

نشانی اینترنتی http://acta.tums.ac.ir/index.php/acta/article/view/3784
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات